monoclonal

Name: CD95 Monoclonal Antibody clone EP208

Description and aplications: The CD95 (Fas) protein is a cell surface receptor belonging to the tumor necrosis factor (TNF) family that transduces death signaling on engagement by multimeric Fas ligand (CD95L), of which there are eight in its membrane–bound form or in its soluble form resulting from cleavage by a putative metalloproteinase. CD95 is a widely expressed protein. CD95-mediated apoptosis is an essential mechanism for the maintenance of normal tissue homeostasis, and disruption of this death pathway has been associated with a wide range of human diseases, including autoimmune diseases, lymphoproliferative disorders and malignancies. The Fas death system also plays important roles in various apoptosis conditions such as those evoked by irradiation, chemotherapeutic
agents and viral infections. The expression of CD95 serves as a prognostic marker in predicting the outcome of disease progression and treatment in many types of tumors.

Composition: Anti-human CD95 rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Name: CNPase Monoclonal Antibody clone 11-5B

Description and aplications: This monoclonal antibody recognises two proteins with a molecular mass of 46 kD (CNP1) and 48 kD (CNP2), identified as CNPase isoforms. CNPase (2’,3’-cyclic nucleotide 3′-phosphodiesterase) is expressed at high levels in oligodendrocytes of the central nervous system and in Schwann cells of the peripheral nervous system and it is virtually absent in other cell types. Since CNPase is expressed early in postnatal development, this antibody is useful for the identification of oligodendrocytes and Schwann cells. CNPase activity is decreased in demyelinating diseases such as multiple sclerosis. The CNPase gene is located on chromosome 17q21, very close to the familial breast cancer gene BRCA1. This antibody shows cross-reactivity with monkey, cow, sheep, goat, pig, cat, dog, rabbit, rat, and mouse. It does not cross-react with guinea pig and chicken.

Composition: Anti-human CNPase mouse monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use: Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Name: Cytokeratin 17 Monoclonal Antibody clone EP98

Description and aplications: The widely known intermediate filaments proteins, which measure between 7 and 22 nm diameter (that is, a size between the one of the actin -5-7 nm and the tubulin -22-25 nm-), along with the previous ones, belong to the cytoskeleton of the vertebrates. This superfamily is made up of six subfamilies of molecules with different tissue expressions. Cytokeratins make up the homology I and II in humans. They are encoded in more than 49 different genes in the chromosomes 17 (I) and 12 (II). The nomenclature adopted in 1982 by Moll and Franke assigns the ranks 1 to 8 for the type II cytokeratins (neutral or basic) and between 9 and 21 for the type I (acid). Nowadays, an analogue nomenclature has been defined to name the hair keratin with theaddition of the Ha and Hb letters to separate the ones of the group I from group II. Structurally speaking, cytokeratins share with the rest of intermediate filaments a central axis of 310 amino acids made up of four α-helices domains (1A, 1B, 2A and 2B) highly preserved that define the type of intermediate filament that they will make up after its packing, separated by three non-helix binding sites (L1, L12 and L2) and two extreme domains highly different in size and sequence (head-1- and tail-2-), each of them with constant (E1/E2), variable (V1/V2) and homology regions (H1/H2), the last ones are characteristic of the type II keratins and absent of the type I. In variable domains, they have the most immunogenic properties and he main differences between each type of keratin. Usually, keratins assemble in heterodimers I/II and they co-express in pairs specifically in each tissue. Cytokeratin 17 of 46 KDa of molecular mass is a type I intermediate filament with an isoelectric point of 5.1 encoded by the gene of the same name located in the chromosome 17. Cytokeratin 17 is expressed in the basal and suprabasal cells of complex epithelium of the skin and skin adnexa. Furthermore, it is expressed in the basal cells of the pseudostratified epithelium of the trachea, larynx and bronchus. This antibody reacts with myoepithelial cells of the salivary and sweat glands. This antibody is useful to diagnose epithelial neoplasias that express cytokeratin 17 such as basal cell carcinomas, squamous lung cancers, adenoid cystic and mucoepidermoid salivary gland carcinomas, mesotheliomas, cholangiocarcinomas and numerous lung adenocarcinomas (>50%), colorectal adenocarcinomas (<50%), pancreatic adenocarcinomas (30%). Cytokeratin 17 is not detected in gastric adenocarcinomas, mucinous colorectal adenocarcinomas, hepatocellular carcinomas and Merkel-cell carcinomas.

Composition: Anti-human Cytokeratin 17 rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Name: PCNA (Proliferating Cell Nuclear Antigen) Monoclonal Antibody clone PC10

Description and aplications: Expression of proliferating cell nuclear antigen (PCNA) or cyclin or polymerase delta auxiliary protein is elevated in the nucleus during late G1 phase immediately before the onset of DNA synthesis, becoming maximal during S-phase and declining during G2 and M phases. Its level correlates directly with rates of cellular proliferation and DNA synthesis. PCNA/cyclin may act as an auxiliary protein of DNA polymerase-delta to play a fundamental role in the initiation of cell proliferation The level of PCNA expression is directly related to the rate of cell proliferation and DNA synthesis. PCNA / cyclin could act as an auxiliary protein of DNA polymerase delta, which plays an essential role in the initiation of cell proliferation.This antibody is useful tool for studying the proliferating cells in normal tissues and its potential aberrant expression in neoplasms

Composition: anti-human PCNA mouse monoclonal antibody purified from ascites fluid by Protein A chromatography. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Immunogen: Recombinant rat PCNA protein

Name:PD-1 Antibody clone NAT105

Description and aplications: Programmed death-1 (PD-1) is a member of the CD28 family of receptors that includes CD28, cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4), inducible costimulator (ICOS), and B- and T-lymphocyte attenuator. These receptors play a role in the cellular immune response. For example, CD28 serves as a costimulatory receptor that enhances T-cell activation, whereas CTLA-4 serves as an inhibitor of T-cell activation. PD-1 also has an inhibitory function on T cells and B cells, and is important in peripheral tolerance. There are at least 2 ligands for PD-1, PD-L1, and PD-L2, which are expressed on a range of cells.
CD28 is constitutively expressed on most or all CD4+ T cells and approximately 50% of CD8+ T cells, whereas CTLA-4 is not expressed on resting T cells. PD-1 is also expressed on activated T cells, B cells, and myeloid cells. Iwai and coworkers studied the microanatomic distribution of PD-1 in human tonsil and found that PD-1 is expressed on most T cells and a small subset of B cells in the light zone of germinal centers, but not elsewhere in the tonsil. On that basis, it was postulated that PD-1 may play a role in the process of clonal selection of centrocytes, which occurs in this subanatomic site in germinal centers.

Composition: anti-human PD-1 mouse monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Name: PD-L1 Monoclonal Antibody clone CAL10

Description and applications:Programmed death ligand 1 (PD-L1, also known as CD274) inhibits tumor-reactive T cells via binding to the programmed death-1 (PD-1) receptor, rendering tumor cells resistant to CD8+ T cell-mediated lysis. Studies have shown that the inhibitory receptor PD-1 is expressed on tumor-infiltrating lymphocytes (TIL) while PD-L1 is expressed on tumor cells. Assessment of PD-L1 expression in combination with CD8+ TIL density may be a useful predictive metric in multiple cancers, including stage III NSCLC, hormone receptor negative breast cancer and sentinel lymph node melanoma. Clinical trials utilizing humanized chimeric antibodies that block inhibitory checkpoints, such as anti-PD-1 and anti-PD-L1, have demonstrated delayed tumor growth and increased survival. While identification of PD-L1 overexpression by IHC is not yet standardized, it has become increasingly  important to identify these tumors, as a directed therapy may improve clinical outcomes in these patients. In cutaneous melanoma, the targeting of PD1/PD-L1 has provided meaningful clinical benefit for patients in just the past 5-10 years. The use of IHC for protein identification, along with novel therapies, such as checkpoint inhibitors and vaccines, are generating new options for the treatment of cancer patients. The PD-L1 [CAL10] clone does not cross react with PDL2.

Composition: Anti-human PD-L1 rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use: Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Immunogen: Peptide corresponding to the region within human PD-L1.

Name: Anti-AMACR/p504s+Anti-p63 human cocktail (PIN cocktail) clone 13H4+4A4

Description and aplications: The main use of the combination of both antibodies in a single reagent is simultaneously immunostain prostate glands in order to detect whether or not neoplastic. In the case of prostate adenocarcinoma, neoplastic glands must present cytoplasmic staining produced by expression of p504s and absence of nuclear staining as these glands lack basal cells and thus are negative for p63. Normal or hyperplastic glands must present nuclear staining in the basal cell layer. The Due to the different pattern of staining of the antibodies included in the cocktail, the detection could be realised with a polyvalent HRP detection systems. Nevertheless, as the antibodies are developed in two different host, a dual detection system can be used.

Composition: anti-human AMACR/p50s rabbit monoclonal antibody + anti-human p63 mouse monoclonal antibody prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Immunogen: Human AMACR polypeptide + aminoacids 1-250 of the N-terminal portion of the human p63 protein

Name: PMS2 Monoclonal Antibody clone EP51

Description and aplications: PMS2, a mismatch repair endonuclease, is a member of a family of genes involved in DNA mismatch repair. Carriers of the mismatch repair gene mutations have a high lifetime risk of developing Hereditary Non-Polyposis Colon Cancer (HNPCC) and several other cancers including endometrial cancer due to microsatellite instability (MSI) caused by accumulation of DNA replication errors in proliferating cells. Along with MLH1, MSH2 and MSH6, PMS2 antibody is helpful in diagnosis of MSI. An IHC study conducted by Mayo clinic on 535 cases with MSI-high, 90% of the tumors showed loss of MLH1, MSH2 and/or MSH6 expression, while 70% of the remaining cases showed isolated loss of PMS2 expression. The loss of PMS2 was associated with young age of diagnosis and right-sided location but not with a striking family history of cancer. Endometrial carcinomas are the most common noncolorectal cancers occur in HNPCC. The most common IHC abnormality in endometrial carcinomas with MSI was concurrent loss of MLH1/PMS2. Adding of PMS2 and MSH6 to MLH1 and MSH2 antibodies increased sensitivity for diagnosis of MSI. Tumors with low-level MSI show unfavourable pathological characteristics compared to tumours with no and tumours with highlevel MSI.

Composition: anti-human PMS2 rabbit monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Immunogen: A synthetic peptide corresponding to residues in human PMS2 protein

Name: PNL2 Monoclonal Antibody clone PNL2

Description and applications: PNL2, initially developed as a human somatostatin receptor marker, is a novel monoclonal antibody directed against an antigen (not well affiliated with melanocytes) that is chemically resistant to fixation and allows immunostaining after melanin bleaching and treatment with decalcifying agents. On a wide range of normal and neoplastic human tissues and compared to other similar markers such as HMB45, Melan A, MiTF, CD63, MAGE1, MAGE3, or tyrosinase, this antibody has revealed high specificity for melanocytes and for various benign and malignant melanocytic lesions derived from them. When the anti-PNL2 antibody is used on normal tissues, it gives a strong cytoplasmic staining of skin and oral mucosae melanocytes, as well as of granulocytes and osteoclast-like multinucleated giant cells when used at high concentration. In benign melanocytic lesions, PNL2 labels intraepidermal nevi, whereas intradermal nevi and the dermal component of compound nevi are basically negative although scattered nevus cells in the papillary dermis are usually positive. In primary melanomas, irrespective of their histologic type, PNL2 usually labels more than 70% of the neoplastic cells. In this context and within a broader panel of antibodies, PNL2 may contribute to the differential diagnosis between atypical nevus lesions and melanomas, although this antibody does not label desmoplastic melanomas. Moreover, the vast majority of metastatic melanomas are positive against PNL2 and, although the proportion of labelled cells is occasionally lower than in the primary tumour, it is always greater than that obtained with the commonly used markers for these tumours (HMB45 and Melan A). Like Melan A and HMB-45, PNL2 also stains most of the clear cell sarcoma cells, and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Other non-melanocytic lesions positive for this antibody include PEComas and melanotic schwannoma. In isolated cases of chronic myeloid leukaemia, the PNL2 antibody stains neutrophils and myelocites, while blast cells are negative.

Composition: Anti-human PNL2 mouse monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Name: p21/Waf-1 (DCS-60.2)

Description and aplications: p21WAF1/Cip1/Sdi1/Pic1 is a tumor suppressor protein. Expression of p21WAF1 is induced by wild type, but not mutant, p53 suppressor protein. The p21WAF1 protein binds to cyclin/CDK complexes and inhibits their kinase activity thereby stopping cell cycle progression. It also binds to PCNA (proliferating cell nuclear antigen) and blocks DNA replication but not the DNA repair process.

Composition: anti-human p21 mouse monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Visualization: Nuclear

Name: Cytokeratin 7 Antibody clone OV-TL 12/30

Description and aplications: Keratins (also known as cytokeratins) are intermediate filament/forming proteins that represents the main cytoskeleton of epithelial cells. They classically are classified based on Moll cataloging which grouped the basic-to-neutral type II keratins as K1–K8 and the acidic type I keratins as K9– K19. An updated classification including 24 types of keratins was then proposed in order to enable other mammalian species keratins to be added. This monoclonal antibody reacts specifically with the cytokeratin 7, immunostaining of the producing a protein band of 54 kD in the cytoskeleton of cell lines and uni-dimensional immunoblots. This antibody is useful to distinguish between different types of normal glandular epithelia as it marks the epithelia of lung and breast, being negative for colon and prostate. We have not observed any cross reaction with other cytokeratins and overall this antibody does not react with stratified squamous epithelium. In liver, hepatocytes are negative and the epithelial cells of the bile ducts are positive. This antibody reacts with numerous both benign and malignant epithelial lesions. Cytokeratin 7 is expressed in specific subtypes of ovarian adenocarcinomas, breast and lung carcinomas while the gastrointestinal tract, except stomach, are negative. Carcinomas arising from transitional epithelium also express cytokeratin, whereas prostate cancer is generally negative.

Composition: anti human keratin 7 mouse monoclonal antibody obtained from supernatant culture and prediluted in a Tris buffered solution pH 7.4 containing 0.375mM sodium azide solution as bacteriostatic and bactericidal.

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Immunogen: OTN II ovarian carcinoma cell line

Name: Cytokeratin 8 antibody clone EP17

Description and aplications: Cytokeratin 8 (CK8) is an intermediate filament protein produced early in embryogenesis. It is the only type-II CK occurring in many simple epithelial in respiratory, gastrointestinal, male and female reproductive tract and thyroid. CK8 is often co-expressed with Cytokeratin 18. CK8/18 is the major keratin pair in simple-type epithelia, as found in the liver, pancreas, and intestine. CK8 antibody is used to detect adenocarcinomas with simple epithelium origin. The difference in staining pattern is useful to distinguish duct (peripheral staining) from lobular (perinuclear staining) breast carcinoma

Composition: anti-human cytokeratin 8 rabbit monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Immunogen: A synthetic peptide corresponding on the C-terminus